A vaccine invented in 1921 to fight tuberculosis just showed it might do something nobody expected: retrain your brain's immune system against Alzheimer's.
Yes, that BCG shot.
The same one most Indians got as babies.
A new study says it may quietly be protecting more than just lungs.
Here's the headline finding.
In a small clinical trial, 23 adults over 55 got two doses of the BCG vaccine, a month apart.
A year later, researchers checked their blood and spinal fluid.
What they found surprised even the scientists.
Normally, a vaccine trains your immune system to fight one specific germ.
BCG did something bigger.
It triggered what scientists call "trained immunity" — a lasting upgrade to how immune cells behave, not just against TB, but broadly.
For the first time ever, researchers found evidence that this kind of deep immune reprogramming can happen inside the human brain's environment, not just in a lab dish.
That's a big deal.
Because Alzheimer's isn't just about memory loss — a huge part of the disease is the brain's immune system malfunctioning and failing to clear toxic buildup.
Among participants who didn't yet have Alzheimer's-related brain changes, something interesting happened.
Levels of amyloid-beta — the sticky protein blamed for clogging the brain in Alzheimer's — started shifting in a favourable direction.
The vaccine appeared to help flush this protein out of the brain and into the bloodstream, where the body can deal with it.
No safety red flags.
No unexpected side effects.
Just a century-old, dirt-cheap vaccine, quietly doing something nobody had proof of before.
This is where it gets personal for a country like ours.
Dr. Mahesh Chandra Kodali, a Harvard neuroscientist who worked on interpreting these findings, put it plainly: if this holds up in bigger trials, it could give India "a far more accessible and affordable strategy than many of the current Alzheimer's treatments."
That's not a small claim.
That's a country of over a billion people already halfway to a solution — without spending a rupee more.
This was a small, single-centre, open-label trial.
No placebo group.
Just 23 people.
Real science doesn't move on hope — it moves on repetition, scale, and scrutiny.
Which is exactly why Dr. Kodali is now pushing for something bigger: a multicentre clinical trial in India, using the country's existing BCG programme as a natural testing ground.
Researchers also built a brand-new tool during this study — a way to directly measure how immune cells around the brain are actually functioning in living people.
Until now, that simply wasn't possible.
That tool alone could speed up research not just for Alzheimer's, but for other brain diseases too.
Somewhere in a hundred-year-old vaccine vial, there might be a clue to one of medicine's toughest unsolved problems.
Not a new billion-dollar drug.
Not a moonshot gene therapy.
Just an old, trusted needle — possibly doing far more than anyone ever gave it credit for.
The next few years of trials will decide if this hope holds up.
But for a rapidly ageing India, this is one story worth watching closely.
That's all for now!
